Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Research Based Observational Study of Poteligeo Experience in the Real World in Adult Patients With Mycosis Fungoides and Sézary Syndrome

Next Previous
Trial Profile

Prospective Research Based Observational Study of Poteligeo Experience in the Real World in Adult Patients With Mycosis Fungoides and Sézary Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Therapeutic Use
  • Acronyms PROSPER
  • Sponsors Kyowa Kirin Pharmaceutical Development

Most Recent Events

  • 08 Oct 2024 According to a Kyowa Kirin media release, today announced it will present interim findings from three real-world studies (MINT (Germany) and MIBERIC (Spain and Portugal) and PROSPER (US, UAE, Spain, Italy, Netherlands, UK)) in cutaneous T-cell lymphoma (CTCL) at the annual meeting of the European Organisation for Research and Treatment of Cancer's Cutaneous Lymphoma Tumour Group (EORTC-CLTG), taking place from 9-11 of Oct 2024 in Lausanne, Switzerland.
  • 04 Sep 2024 Status changed from recruiting to active, no longer recruiting.
  • 17 Jun 2024 Planned End Date changed from 5 Sep 2024 to 7 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top